This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IBM Backs Anti-Counterfeiting Startup

BOSTON ( TheStreet) -- IBM (IBM - Get Report) selected a Boston-area startup that aims to rid the world of counterfeit medicine in a business-idea competition.

Sproxil won the Boston installment of IBM SmartCamp, a competition that provides networking opportunities to a select group of technology startups.

To qualify for SmartCamp, a startup must be younger than 3 years old with maximum annual sales of less than $1 million. Throughout the year, IBM will be running one-day SmartCamp programs in Paris, Tel Aviv, Silicon Valley, Boston, Stockholm and London.

At the end of each event, Big Blue chooses a company from each city to attend SmartCamp week in Dublin (Nov. 15), where the worldwide winner will be named. There's no direct cash prize -- the grand prize is a few months of mentorship from IBM officials -- but of the five startups that made it to the finals last year, four received significant funding offers from angel investors.

Sproxil uses cell-phone-based authentication technology to help prevent counterfeit drugs in developing countries. Consumers scratch off a security code on the medicine bottle -- like with a lottery ticket -- and then they text the code to Sproxil from their cell phones. If the code is legitimate, consumers immediately receive a confirmation message. The technology will work with any phone that supports texting.

Drug counterfeiting is, by some estimates, a problem that generates tens of billions of dollars annually for criminals. Recent counterfeiting schemes resulted in sales of fake and ineffective versions of the Genentech (DNA) anti-obesity drug Xenical and the anti-malarial drug Metakelfin, according to the World Health Organization.

-- Reported by Carmen Nobel in Boston.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IBM $145.46 -1.10%
AAPL $93.39 -1.50%
FB $116.46 -0.23%
GOOG $691.66 0.09%
TSLA $238.65 -3.70%


Chart of I:DJI
DOW 17,703.69 -127.07 -0.71%
S&P 500 2,060.38 -15.43 -0.74%
NASDAQ 4,772.0860 -33.2050 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs